By Sabela OjeaShares of Lexicon Pharmaceuticals on Friday rose 6.6% to $3.39 in after-hours trading following news the company's heart-failure treatment Inpefa received U.S. Food and Administration approval. The biopharmaceutical company said the approval of Inpefa, expected to be commercially available in the U.S. by the end of June, was based on the outcomes of two Phase 3 cardiovascular studies. Inpefa, a once-daily oral tablet known generically as sotagliflozin, targets the risk of cardiovascular death, urgent heart failure medical visits and hospitalizations in adults with heart failure of type 2 diabetes mellitus and chronic kidney disease, among other cardiovascular risk factors. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix(END) Dow Jones Newswires05-26-23 1710ET

Source: Wall Street Journal May 27, 2023 09:10 UTC